NR4A1 and ductal breast carcinoma in situ: <h4>Background</h4>The clinical benefits of adjuvant endocrine therapy for patients with hormone receptor (HR)-positive ductal carcinoma in situ (DCIS) undergoing mastectomy remain controversial.